| 词条 | Lonafarnib |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 462093478 | ImageFile=Lonafarnib.svg | ImageSize=200px | IUPACName=4-(24-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]piperidin-1-yl2-oxoethyl)piperidine-1-carboxamide | OtherNames= Sarasar (US), SCH 66336 |Section1={{Chembox Identifiers | UNII_Ref = {{fdacite|correct|FDA}} | UNII = IOW153004F | IUPHAR_ligand = 8024 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 130645 | InChI = 1/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1 | InChIKey = DHMTURDWPRKSOA-RUZDIDTEBQ | ChEBI_Ref = {{ebicite|changed|EBI}} | ChEBI = 47097 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 298734 | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = DHMTURDWPRKSOA-RUZDIDTESA-N | CASNo_Ref = {{cascite|changed|??}} | CASNo=193275-84-2 | PubChem=148195 | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D04768 | SMILES = C=12CCC=3C=C(C=C(C3[C@H](C1N=CC(=C2)Br)C4CCN(CC4)C(=O)CC5CCN(CC5)C(N)=O)Br)Cl }} |Section2={{Chembox Properties | Formula=C27H31Br2ClN4O2 | MolarMass=638.82164 | Appearance= | Density= | MeltingPt= | BoilingPt= | Solubility= |Section3={{Chembox Hazards | MainHazards= | FlashPt= | AutoignitionPt = }}Lonafarnib is a farnesyltransferase inhibitor (FTI) that has been investigated in a human clinical trial as a treatment for progeria, which is an extremely rare genetic disorder in which symptoms resembling aspects of aging are manifested at a very early age.[1][2] Lonafarnib is a synthetic tricyclic halogenated carboxamide with antineoplastic properties.[3] As such, it is used primarily for cancer treatment. For those with progeria, research has shown that the drug reduces the prevalence of stroke and transient ischemic attack, and the prevalence and frequency of headaches while taking the medication.[4] A phase II clinical trial was completed in 2012, which showed that a cocktail of drugs that included lonafarnib and two other drugs met clinical efficacy endpoints that improved the height and diminished the rigidity of the bones of progeria patients.{{cn|date=May 2014}} References1. ^{{cite journal |author=Liu G |title=Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336) |journal=Anticancer Drugs |volume=18 |issue=8 |pages=923–31 |year=2007 |pmid=17667598 |doi=10.1097/CAD.0b013e3280c1416e |name-list-format=vanc|author2=Marrinan CH |author3=Taylor SA |display-authors=3 |last4=Black |first4=S |last5=Basso |first5=AD |last6=Kirschmeier |first6=P |last7=Robert Bishop |first7=W |last8=Liu |first8=M |last9=Long |first9=BJ|doi-broken-date=2018-09-22 }} 2. ^[https://www.progeriaresearch.org/the-fti-drug/ “The FTI Drug Lonafarnib”], Progeria Research Foundation. Accessed October 3, 2017. 3. ^{{cite web | url = http://www.cancer.gov/drugdictionary?cdrid=43503 | title = Lonafarnib | work = NCI Drug Dictionary | publisher = National Cancer Institute}} 4. ^{{cite journal | doi = 10.1212/WNL.0b013e31829d85c0 | title = Neurologic features of Hutchinson–Gilford progeria syndrome after lonafarnib treatment | year = 2013 | last1 = Ullrich | first1 = N. J. | last2 = Kieran | first2 = M. W. | last3 = Miller | first3 = D. T. | last4 = Gordon | first4 = L. B. | last5 = Cho | first5 = Y.-J. | last6 = Silvera | first6 = V. M. | last7 = Giobbie-Hurder | first7 = A. | last8 = Neuberg | first8 = D. | last9 = Kleinman | first9 = M. E. | journal = Neurology | volume = 81 | issue = 5 | pages = 427–30 | pmid = 23897869 | pmc = 3776537 }} See also
External links
6 : Piperidines|Ureas|Benzocycloheptapyridines|Organobromides|Chloroarenes|Farnesyltransferase inhibitors |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。